tradingkey.logo

Predictive Oncology Inc

POAI
7.210USD
-1.030-12.50%
Cierre 11/04, 16:00ETCotizaciones retrasadas 15 min
4.61MCap. mercado
PérdidaP/E TTM

Predictive Oncology Inc

7.210
-1.030-12.50%

Más Datos de Predictive Oncology Inc Compañía

Predictive Oncology Inc. is a knowledge-driven company focused on applying artificial intelligence (AI) to support the development of cancer therapies. The Company operates through three segments: Pittsburgh, Birmingham, and Eagan. Pittsburgh segment provides services, which include the application of artificial intelligence (AI) using its proprietary biobank of 150,000 plus tumor samples. Pittsburgh segment also develops tumor-specific in vitro models for oncology drug discovery and research. Birmingham segment focuses on contract services and research for biopharmaceutical company clients and academic collaborators, focused on solubility improvements, stability studies, and protein production. Specifically, Birmingham provides optimized formulations for vaccines, antibodies, and other protein therapeutics. Eagan segment produces the STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal.

Información de Predictive Oncology Inc

Símbolo de cotizaciónPOAI
Nombre de la empresaPredictive Oncology Inc
Fecha de salida a bolsaDec 18, 2009
Director ejecutivoMr. Raymond F. Vennare
Número de empleados23
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 18
Dirección91 43Rd Street
CiudadPITTSBURGH
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal15201
Teléfono14124321500
Sitio Webhttps://predictive-oncology.com/
Símbolo de cotizaciónPOAI
Fecha de salida a bolsaDec 18, 2009
Director ejecutivoMr. Raymond F. Vennare

Ejecutivos de Predictive Oncology Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Raymond F. Vennare
Mr. Raymond F. Vennare
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
8.81K
--
Mr. Joshua Blacher
Mr. Joshua Blacher
Interim Chief Financial Officer
Interim Chief Financial Officer
6.47K
--
Dr. Daniel E. (Dan) Handley, Ph.D.
Dr. Daniel E. (Dan) Handley, Ph.D.
Independent Director
Independent Director
5.45K
--
Dr. Veena Rao, Ph.D.
Dr. Veena Rao, Ph.D.
Independent Director
Independent Director
4.92K
--
Mr. Thomas McLaughlin
Mr. Thomas McLaughlin
Chief Investment Officer
Chief Investment Officer
--
--
Ms. Sara Turken
Ms. Sara Turken
General Counsel
General Counsel
--
--
Mr. Shawn P. Matthews
Mr. Shawn P. Matthews
Director
Director
--
--
Dr. Matthew J. Hawryluk, Ph.D.
Dr. Matthew J. Hawryluk, Ph.D.
Independent Director
Independent Director
--
--
Mr. Gregory S. St. Clair, Sr.
Mr. Gregory S. St. Clair, Sr.
Independent Director
Independent Director
--
--
Mr. Chuck (Charles) Nuzum, Sr.
Mr. Chuck (Charles) Nuzum, Sr.
Lead Independent Director
Lead Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Raymond F. Vennare
Mr. Raymond F. Vennare
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
8.81K
--
Mr. Joshua Blacher
Mr. Joshua Blacher
Interim Chief Financial Officer
Interim Chief Financial Officer
6.47K
--
Dr. Daniel E. (Dan) Handley, Ph.D.
Dr. Daniel E. (Dan) Handley, Ph.D.
Independent Director
Independent Director
5.45K
--
Dr. Veena Rao, Ph.D.
Dr. Veena Rao, Ph.D.
Independent Director
Independent Director
4.92K
--
Mr. Thomas McLaughlin
Mr. Thomas McLaughlin
Chief Investment Officer
Chief Investment Officer
--
--
Ms. Sara Turken
Ms. Sara Turken
General Counsel
General Counsel
--
--

Desglose de ingresos

Sin datos
Sin datos
Por negocio
Por región
Sin datos

Estadísticas de accionistas

Actualizado: jue., 30 de oct
Actualizado: jue., 30 de oct
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Luo (Weiyu)
12.28%
SLN Capital Ltd
7.37%
Vennare (Raymond F)
0.25%
Blacher (Joshua)
0.18%
Nuzum (Charles Lee Sr)
0.18%
Otro
79.73%
Accionistas
Accionistas
Proporción
Luo (Weiyu)
12.28%
SLN Capital Ltd
7.37%
Vennare (Raymond F)
0.25%
Blacher (Joshua)
0.18%
Nuzum (Charles Lee Sr)
0.18%
Otro
79.73%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
13.66%
Corporation
7.37%
Investment Advisor/Hedge Fund
0.15%
Investment Advisor
0.14%
Research Firm
0.03%
Endowment Fund
0.02%
Otro
78.63%

Participación institucional

Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
36
12.13K
0.35%
-21.27K
2025Q2
44
299.51K
2.93%
-288.64K
2025Q1
50
299.35K
3.35%
-293.31K
2024Q4
56
353.94K
4.97%
-213.96K
2024Q3
54
322.08K
5.97%
-246.26K
2024Q2
57
408.73K
8.00%
-114.07K
2024Q1
66
484.20K
11.91%
-86.59K
2023Q4
66
502.45K
12.36%
-67.11K
2023Q3
69
499.46K
12.41%
-50.95K
2023Q2
67
353.15K
8.84%
-144.84K
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Vennare (Raymond F)
8.81K
1.16%
+8.33K
+1753.89%
Sep 09, 2025
Blacher (Joshua)
6.47K
0.85%
+6.47K
--
Sep 09, 2025
Nuzum (Charles Lee Sr)
6.31K
0.83%
+4.31K
+216.25%
Sep 09, 2025
St Clair (Gregory Sr)
5.72K
0.75%
+4.31K
+305.17%
Sep 09, 2025
Chung-Welch (Nancy)
5.60K
0.73%
+4.31K
+334.78%
Sep 09, 2025
Handley (Daniel E)
5.45K
0.71%
+4.31K
+379.91%
Sep 09, 2025
Hawryluk (Matthew)
4.95K
0.65%
+4.31K
+681.20%
Sep 09, 2025
Rao (Veena)
4.92K
0.65%
+4.31K
+709.21%
Sep 09, 2025
Ver más

ETFs relacionados

Actualizado: dom., 2 de nov
Actualizado: dom., 2 de nov
Nombre
Proporción
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proporción0%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Tipo
Relación
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
Fecha
Tipo
Relación
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
Apr 20, 2023
Merger
20→1
KeyAI